STATEMENT OF NEED
With the complex and rapidly evolving treatment landscape of multiple myeloma, it is vital that clinicians not only understand factors for informing selection of current and emerging combination and sequential therapeutic strategies, but also employ interdisciplinary strategies for reducing disparities in relapsed/refractory multiple myeloma care. The development of novel therapeutic options has significantly improved treatment outcomes for patients with relapsed/refractory multiple myeloma; however, many patients face barriers to timely and appropriate treatment, including racial, ethnic, and socioeconomic disparities in health care delivery and services. While Black patients with multiple myeloma are more likely to have a lower-risk genetic profile, multiple myeloma remains twice as deadly in Black patients compared with White patients. Both Black and Hispanic patients experience a longer time from diagnosis to novel therapy initiation compared with non-Hispanic White patients, and they are also less likely to receive autologous stem cell transplant. Additionally, Black and Hispanic patients, as well as patients who are older or live in rural areas, are underrepresented in clinical trials of novel therapies, creating a poor reflection of the real-world patient population (Multiple Myeloma Research Foundation, 2023). In order to provide optimal health care delivery, this Multiple Myeloma Task Force will provide a consensus opinion on mitigating disease burden and health care disparities in relapsed/refractory multiple myeloma. The Multiple Myeloma Task Force includes co-chairs Sikander Ailawadhi, MD, Professor of Medicine at the Mayo Clinic and Rahul Banerjee, MD, FACP, Assistant Professor of Medical Oncology at Fred Hutchinson Cancer Center and the University of Washington; and faculty members Yelak Biru, MSc, President and CEO of the International Myeloma Foundation; Craig Cole, MD, Assistant Professor at Karmanos Cancer Institute; Beth Faiman, PhD, APN-BC, Nurse Practitioner at the Cleveland Clinic Taussig Cancer Center; and Shonali Midha, Medical Oncologist at Dana-Farber Cancer Institute.
Hematology/oncology physicians, nurse practitioners, physician assistants/associates oncology nurses, patient advocates, and other health care professionals involved in the management of patients with relapsed/refractory multiple myeloma.
Upon completion of this activity, participants should be able to
- Identify factors that can inform treatment selection for individual patients with RRMM
- Explain the clinical significance of measurable residual disease (MRD) negativity in the management of MM
- Distinguish current and emerging combination and sequential treatment strategies for MM patients experiencing early relapse and late relapse
- Assess interdisciplinary strategies for reducing disparities in MM care
There is no fee to view this live presentation.
This activity is supported by an independent educational grant from Sanofi.
Sikander Ailawadhi, MD (Co-Chair)
Sikander Ailawadhi, MD, is a Professor of Medicine in the Division of Hematology/Oncology and Lead of the International Cancer Center at the Mayo Clinic in Jacksonville, Florida. He specializes in the treatment of multiple myeloma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, and other hematologic malignancies. Dr. Ailawadhi is passionate about reducing health care disparities experienced by ethnic minorities and improving health care outcomes across populations.
Rahul Banerjee, MD, FACP (Co-Chair)
Rahul Banerjee, MD, FACP, is an Assistant Professor in the Division of Medical Oncology at the University of Washington and Fred Hutchinson Cancer Center. He previously completed his Hematology/Oncology Fellowship and Advanced BMT/CAR-T Fellowship at the University of California, San Francisco. Dr. Banerjee’s clinical interests are in multiple myeloma, AL amyloidosis, and CAR T-cell therapy, and his research interests are in toxicity management, digital health, and the patient experience.
Yelak Biru, MSC
Yelak Biru, MSC, is President and Chief Executive Officer of the International Myeloma Foundation. Having lived with multiple myeloma for more than two decades, he is passionate about improving quality of life for patients with multiple myeloma, advocating for equitable health care access, and fostering support and education for patients and caregivers. Through his leadership, the International Myeloma Foundation has conducted over 50 ongoing research studies worldwide.
Craig Cole, MD
Craig Cole, MD, is an Assistant Professor in the Division of Hematology and Oncology at Karmanos Cancer Institute in Lansing, Michigan. He specializes in the treatment of multiple myeloma, non-Hodgkin lymphoma, and myelodysplasia, and he has published numerous studies and has presented his work at several large national conferences. Dr. Cole is dedicated to emphasizing patient empowerment and education, and he works in collaboration with several local and national patient advocacy associations.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, is a Nurse Practitioner in the Department of Hematologic Oncology and Blood Disorders at the Cleveland Clinic Taussig Cancer Center. She specializes in the treatment of multiple myeloma, with a particular focus on symptom management, education, and bringing new knowledge to underserved areas. Dr. Faiman is an internationally renowned expert in cancer nursing, and she has published and presented her research at numerous national conferences.
Shonali Midha, MD
Shonali Midha, MD, is a Medical Oncologist at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School. She specializes in the treatment of multiple myeloma and plasma cell disorders. Dr. Midha’s research focuses on the role of immunotherapy and cellular therapies in multiple myeloma and on better understanding high-risk disease.
We look forward to you joining us on Thursday, November 30th!
SAVE THE DATE for this live discussion to hear perspectives on:
- The role that racial and socioeconomic disparities play in preventing patients from receiving optimal therapy for multiple myeloma and what initiatives are underway to reduce these disparities
- How to select treatment for patients with relapsed and refractory myeloma
- When to refer multiple myeloma patients for CAR T-cell therapy or bispecific antibody therapy
- The role that measurable residual disease (MRD) testing plays in multiple myeloma treatment
- Resources to keep physicians informed on practice-changing developments in multiple myeloma treatment
Subscribe to the i3 Health Youtube Channel